{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:45:30Z","timestamp":1768506330926,"version":"3.49.0"},"posted":{"date-parts":[[2023,9,29]]},"group-title":"Biochemistry","reference-count":63,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,9,29]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  We have witnessed three coronavirus (CoV) outbreaks in the past two decades, including the COVID-19 pandemic caused by SARS-CoV-2. Main protease (M\n                  <jats:sup>Pro<\/jats:sup>\n                  ) is a highly conserved and essential protease that plays key roles in viral replication and pathogenesis among various CoVs, representing one of the most attractive drug targets for antiviral drug development. Traditional antiviral drug development strategies focus on the pursuit of high-affinity binding inhibitors against M\n                  <jats:sup>Pro<\/jats:sup>\n                  . However, this approach often suffers from issues such as toxicity, drug resistance, and a lack of broad-spectrum efficacy. Targeted protein degradation represents a promising strategy for developing next-generation antiviral drugs to combat infectious diseases. Here we leverage the proteolysis targeting chimera (PROTAC) technology to develop a new class of small-molecule antivirals that induce the degradation of SARS-CoV-2 M\n                  <jats:sup>Pro<\/jats:sup>\n                  . Our previously developed M\n                  <jats:sup>Pro<\/jats:sup>\n                  inhibitors MPI8 and MPI29 were used as M\n                  <jats:sup>Pro<\/jats:sup>\n                  ligands to conjugate a CRBN E3 ligand, leading to compounds that can both inhibit and degrade SARS-CoV-2 M\n                  <jats:sup>Pro<\/jats:sup>\n                  . Among them, MDP2 was demonstrated to effectively reduce M\n                  <jats:sup>Pro<\/jats:sup>\n                  protein levels in 293T cells (DC\n                  <jats:sub>50<\/jats:sub>\n                  = 296 nM), relying on a time-dependent, CRBN-mediated, and proteasome-driven mechanism. Furthermore, MPD2 exhibited remarkable efficacy in diminishing M\n                  <jats:sup>Pro<\/jats:sup>\n                  protein levels in SARS-CoV-2-infected A549-ACE2 cells, concurrently demonstrating potent anti-SARS-CoV-2 activity (EC\n                  <jats:sub>50<\/jats:sub>\n                  = 492 nM). This proof-of-concept study highlights the potential of PROTAC-mediated targeted protein degradation of M\n                  <jats:sup>Pro<\/jats:sup>\n                  as an innovative and promising approach for COVID-19 drug discovery.\n                <\/jats:p>","DOI":"10.1101\/2023.09.29.560163","type":"posted-content","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T21:25:14Z","timestamp":1696022714000},"source":"Crossref","is-referenced-by-count":5,"title":["Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease"],"prefix":"10.64898","author":[{"given":"Yugendar R.","family":"Alugubelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2497-3187","authenticated-orcid":false,"given":"Kaustav","family":"Khatua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sathish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu R.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerabhadra R.","family":"Vulupala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep R.","family":"Atla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Blankenship","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demonta","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1240-8954","authenticated-orcid":false,"given":"Benjamin W.","family":"Neuman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7078-6534","authenticated-orcid":false,"given":"Wenshe Ray","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6260-9290","authenticated-orcid":false,"given":"Shiqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2023100502150720000_2023.09.29.560163v1.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2147"},{"key":"2023100502150720000_2023.09.29.560163v1.2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1602.090469"},{"key":"2023100502150720000_2023.09.29.560163v1.3","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3389\/fimmu.2020.00811","article-title":"Commentary: Origin and evolution of pathogenic coronaviruses","volume":"11","year":"2020","journal-title":"Front Immunol"},{"key":"2023100502150720000_2023.09.29.560163v1.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-018-0118-9"},{"key":"2023100502150720000_2023.09.29.560163v1.5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-micro-020518-115759"},{"key":"2023100502150720000_2023.09.29.560163v1.6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.57.4.933"},{"key":"2023100502150720000_2023.09.29.560163v1.7","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-121-30734"},{"issue":"2","key":"2023100502150720000_2023.09.29.560163v1.8","first-page":"152","article-title":"Severe acute respiratory syndrome (SARS): a review","volume":"4","year":"2004","journal-title":"Clin Med (Lond)"},{"key":"2023100502150720000_2023.09.29.560163v1.9","doi-asserted-by":"publisher","DOI":"10.18683\/germs.2019.1155"},{"key":"2023100502150720000_2023.09.29.560163v1.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017"},{"key":"2023100502150720000_2023.09.29.560163v1.11","doi-asserted-by":"crossref","first-page":"100682","DOI":"10.1016\/j.genrep.2020.100682","article-title":"Genomic characterization of a novel SARS-CoV-2","volume":"19","year":"2020","journal-title":"Gene Reports"},{"key":"2023100502150720000_2023.09.29.560163v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.04.011"},{"key":"2023100502150720000_2023.09.29.560163v1.13","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25681"},{"key":"2023100502150720000_2023.09.29.560163v1.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-018-0118-9"},{"key":"2023100502150720000_2023.09.29.560163v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2015.09.013"},{"key":"2023100502150720000_2023.09.29.560163v1.16","doi-asserted-by":"crossref","first-page":"104260","DOI":"10.1016\/j.meegid.2020.104260","article-title":"Genetic diversity and evolution of SARS-CoV-2","volume":"81","year":"2020","journal-title":"Infection, Genetics and Evolution"},{"key":"2023100502150720000_2023.09.29.560163v1.17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.12688\/f1000research.22457.2","article-title":"Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates","volume":"9","year":"2020","journal-title":"F1000Research"},{"issue":"17","key":"2023100502150720000_2023.09.29.560163v1.18","doi-asserted-by":"crossref","first-page":"127377","DOI":"10.1016\/j.bmcl.2020.127377","article-title":"The SARS-CoV-2 main protease as drug target","volume":"30","year":"2020","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"23","key":"2023100502150720000_2023.09.29.560163v1.19","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1021\/jm200870n","article-title":"Structure-Based Design, Synthesis, and Evaluation of Peptide-Mimetic SARS 3CL Protease Inhibitors","volume":"54","year":"2011","journal-title":"Journal of Medicinal Chemistry"},{"key":"2023100502150720000_2023.09.29.560163v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112711"},{"key":"2023100502150720000_2023.09.29.560163v1.21","doi-asserted-by":"publisher","DOI":"10.1126\/science.1085658"},{"key":"2023100502150720000_2023.09.29.560163v1.22","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl478"},{"issue":"13","key":"2023100502150720000_2023.09.29.560163v1.23","doi-asserted-by":"crossref","first-page":"8686","DOI":"10.1021\/acs.jmedchem.2c00404","article-title":"Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir","volume":"65","year":"2022","journal-title":"Journal of Medicinal Chemistry"},{"key":"2023100502150720000_2023.09.29.560163v1.24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.omtn.2023.03.013","article-title":"Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?","volume":"32","year":"2023","journal-title":"Molecular Therapy - Nucleic Acids"},{"issue":"8","key":"2023100502150720000_2023.09.29.560163v1.25","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1021\/acscentsci.3c00538","article-title":"Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir","volume":"9","year":"2023","journal-title":"ACS Central Science"},{"key":"2023100502150720000_2023.09.29.560163v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.11.031"},{"key":"2023100502150720000_2023.09.29.560163v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-019-0362-y"},{"key":"2023100502150720000_2023.09.29.560163v1.28","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.9b00597"},{"key":"2023100502150720000_2023.09.29.560163v1.29","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2019.1659242"},{"issue":"8","key":"2023100502150720000_2023.09.29.560163v1.30","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: An Emerging Therapeutic Modality in Precision Medicine","volume":"27","year":"2020","journal-title":"Cell Chem Biol"},{"key":"2023100502150720000_2023.09.29.560163v1.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2019.02.022"},{"key":"2023100502150720000_2023.09.29.560163v1.32","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202003500"},{"key":"2023100502150720000_2023.09.29.560163v1.33","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.7b00247"},{"key":"2023100502150720000_2023.09.29.560163v1.34","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1858"},{"issue":"1","key":"2023100502150720000_2023.09.29.560163v1.35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","article-title":"The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study","volume":"25","year":"2018","journal-title":"Cell Chem Biol"},{"issue":"1","key":"2023100502150720000_2023.09.29.560163v1.36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.chembiol.2017.10.005","article-title":"A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader","volume":"25","year":"2018","journal-title":"Cell Chem Biol"},{"key":"2023100502150720000_2023.09.29.560163v1.37","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2329"},{"issue":"19","key":"2023100502150720000_2023.09.29.560163v1.38","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1002\/anie.201901336","article-title":"Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6","volume":"58","year":"2019","journal-title":"Angew Chem Int Ed"},{"key":"2023100502150720000_2023.09.29.560163v1.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08027-7"},{"issue":"1","key":"2023100502150720000_2023.09.29.560163v1.40","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead","volume":"25","year":"2018","journal-title":"Cell Chem Biol"},{"key":"2023100502150720000_2023.09.29.560163v1.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.10.002"},{"key":"2023100502150720000_2023.09.29.560163v1.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2013.12.025"},{"key":"2023100502150720000_2023.09.29.560163v1.43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11429-w"},{"issue":"1","key":"2023100502150720000_2023.09.29.560163v1.44","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1038\/s41467-020-17997-6","article-title":"Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry","volume":"11","year":"2020","journal-title":"Nat Commun"},{"issue":"11","key":"2023100502150720000_2023.09.29.560163v1.45","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.drudis.2020.08.007","article-title":"Could PROTACs Protect Us From COVID-19?","volume":"25","year":"2020","journal-title":"Drug Discovery Today"},{"issue":"1","key":"2023100502150720000_2023.09.29.560163v1.46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1021\/acsbiomedchemau.2c00063","article-title":"Targeted Protein Degradation for Infectious Diseases: from Basic Biology to Drug Discovery","volume":"3","year":"2023","journal-title":"ACS Bio & Med Chem Au"},{"issue":"3","key":"2023100502150720000_2023.09.29.560163v1.47","doi-asserted-by":"crossref","first-page":"100092","DOI":"10.1016\/j.cellin.2023.100092","article-title":"Antiviral PROTACs: Opportunity borne with challenge","volume":"2","year":"2023","journal-title":"Cell Insight"},{"issue":"8","key":"2023100502150720000_2023.09.29.560163v1.48","doi-asserted-by":"crossref","first-page":"e28981","DOI":"10.1002\/jmv.28981","article-title":"Revolutionizing viral disease treatment: PROTACs therapy could be the ultimate weapon of the future","volume":"95","year":"2023","journal-title":"Journal of Medical Virology"},{"issue":"1","key":"2023100502150720000_2023.09.29.560163v1.49","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1038\/s41467-019-11429-w","article-title":"Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations","volume":"10","year":"2019","journal-title":"Nature Communications"},{"key":"2023100502150720000_2023.09.29.560163v1.50","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202000924"},{"key":"2023100502150720000_2023.09.29.560163v1.51","doi-asserted-by":"publisher","DOI":"10.1126\/science.1085658"},{"key":"2023100502150720000_2023.09.29.560163v1.52","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01461"},{"issue":"2","key":"2023100502150720000_2023.09.29.560163v1.53","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1021\/acscentsci.1c00910","article-title":"Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay","volume":"8","year":"2022","journal-title":"ACS Central Science"},{"issue":"1","key":"2023100502150720000_2023.09.29.560163v1.54","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1038\/s41467-020-18233-x","article-title":"Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease","volume":"11","year":"2020","journal-title":"Nat Commun"},{"issue":"8","key":"2023100502150720000_2023.09.29.560163v1.55","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","year":"2020","journal-title":"Cell Res"},{"issue":"3","key":"2023100502150720000_2023.09.29.560163v1.56","first-page":"370","article-title":"Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics","volume":"12","year":"2020","journal-title":"Rsc Med Chem"},{"key":"2023100502150720000_2023.09.29.560163v1.57","doi-asserted-by":"crossref","first-page":"114596","DOI":"10.1016\/j.ejmech.2022.114596","article-title":"A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals","volume":"240","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"27","key":"2023100502150720000_2023.09.29.560163v1.58","doi-asserted-by":"crossref","first-page":"11734","DOI":"10.1021\/jacs.9b13907","article-title":"Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs","volume":"142","year":"2020","journal-title":"J Am Chem Soc"},{"key":"2023100502150720000_2023.09.29.560163v1.59","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.119"},{"key":"2023100502150720000_2023.09.29.560163v1.60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2012201118"},{"key":"2023100502150720000_2023.09.29.560163v1.61","doi-asserted-by":"crossref","unstructured":"Kumar, P. ; Nagarajan, A. ; Uchil, P. D. Analysis of Cell Viability by the MTT Assay Cold Spring Harb Protoc [Online], 2018. PubMed. http:\/\/europepmc.org\/abstract\/MED\/29858338 z10.1101\/pdb.prot095505 (accessed 2018\/06\/\/).","DOI":"10.1101\/pdb.prot095505"},{"issue":"3","key":"2023100502150720000_2023.09.29.560163v1.62","doi-asserted-by":"crossref","first-page":"e0066522","DOI":"10.1128\/spectrum.00665-22","article-title":"Receptor-Binding-Motif-Targeted Sanger Sequencing: a Quick and Cost-Effective Strategy for Molecular Surveillance of SARS-CoV-2 Variants","volume":"10","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"31","key":"2023100502150720000_2023.09.29.560163v1.63","doi-asserted-by":"crossref","first-page":"20387","DOI":"10.1039\/D2RA02885A","article-title":"A validated LC-MS\/MS analytical method for the quantification of pemigatinib: metabolic stability evaluation in human liver microsomes","volume":"12","year":"2022","journal-title":"RSC Advances"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.09.29.560163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:18:19Z","timestamp":1768454299000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2023.09.29.560163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":63,"URL":"https:\/\/doi.org\/10.1101\/2023.09.29.560163","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1021\/acs.jmedchem.3c02416","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,9,29]]},"subtype":"preprint"}}